InfiniFluidics, a member company based at the Pennovation Center, was recently highlighted in a WHYY News story exploring how artificial intelligence is accelerating breakthroughs in biotechnology and drug development.
The article focuses on a visit by U.S. Senator David McCormick to Penn’s AIRFoundry, an AI-powered research hub that is bringing together robotics, automation, and advanced data processing to transform how new therapies are discovered and developed. The facility represents a growing convergence of disciplines, where engineers, computer scientists, and biologists collaborate to dramatically shorten development timelines and unlock new possibilities in medicine.
InfiniFluidics has developed a prototype system that integrates robotics and AI-driven analysis to accelerate the creation of RNA-based drug treatments. Their work reflects a broader shift in biotech, where emerging tools are enabling researchers to move faster—from early experimentation to real-world applications
This research environment, fueled by collaboration and supported by strong academic and industry partnerships, is designed to reduce the time and cost traditionally required for drug discovery while improving precision and scalability. Technologies like those developed by InfiniFluidics have the potential to help researchers test, refine, and advance therapies more efficiently—benefiting not only human health, but also applications across agriculture and veterinary science.
The recognition of InfiniFluidics in this story underscores the strength of the innovation community at Pennovation Works, where startups are translating cutting-edge research into impactful solutions. As AI continues to reshape the life sciences sector, companies like InfiniFluidics are playing an important role in demonstrating how these tools can be applied to real-world challenges.
Read the article.
